SCHEMBL6784347

SCHEMBL6784347

CCC(C)COc1ccc(N(C)C(=O)CC2(O)CCN(Cc3ccccc3)CC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.45
PKM P14618 1/20 0.45
FAAH O00519 2/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
DRD4 P21917 1/20 0.41
FFAR1 O14842 1/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP2D6 P10635 3/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KMT2A Q03164 3/20 0.40
MMP1 P03956 3/20 0.40
MMP9 P14780 3/20 0.40
MMP13 P45452 3/20 0.40
ADAM17 P78536 3/20 0.40
MEN1 O00255 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6783406 0.89 PKM (0.56) MAPK1PKMFAAHLMNASMN1; SMN2
SCHEMBL6784170 0.87 KMT2A (0.54) MAPK1PKMFAAHLMNASMN1; SMN2
SCHEMBL6789881 0.85 FAAH (0.51) MAPK1PKMFAAHDRD4ALDH1A1
SCHEMBL6789155 0.84 DRD4 (0.47) MAPK1PKMFAAHLMNASMN1; SMN2
SCHEMBL6784761 0.84 CYP2D6 (0.54) FAAHDRD4ALDH1A1CYP2D6TSHR
SCHEMBL6789240 0.83 ALDH1A1 (0.39) MAPK1PKMFAAHLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL6783679 0.82 POLB (0.39) MAPK1PKMFAAHLMNASMN1; SMN2
SCHEMBL6784345 0.81 DRD4 (0.43) MAPK1PKMLMNASMN1; SMN2KDM4E
SCHEMBL6783277 0.80 DRD4 (0.50) FAAHLMNADRD4CYP2D6CYP2C9
SCHEMBL6781033 0.79 FAAH (0.48) FAAHSMN1; SMN2DRD4KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6710060-B2 4-hydroxypiperidine derivatives having antiarrhythmic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2004-03-23 US disclosed
US-20020188006-A1 4-hydroxypiperidine derivatives having antiarrhythmic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-12-12 US disclosed
EP-1182192-A1 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020188006-A1 4-hydroxypiperidine derivatives having antiarrhythmic activity SCN5A, RYR2, SCN1B MAPK1 721/4885PKM 928/4885FAAH 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.